TW202302095A - 使用bet抑制劑治療骨髓纖維化 - Google Patents
使用bet抑制劑治療骨髓纖維化 Download PDFInfo
- Publication number
- TW202302095A TW202302095A TW111107087A TW111107087A TW202302095A TW 202302095 A TW202302095 A TW 202302095A TW 111107087 A TW111107087 A TW 111107087A TW 111107087 A TW111107087 A TW 111107087A TW 202302095 A TW202302095 A TW 202302095A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- formula
- aspects
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Disintegrating Or Milling (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382163 | 2021-02-25 | ||
| EP21382163.0 | 2021-02-25 | ||
| US202163232866P | 2021-08-13 | 2021-08-13 | |
| US63/232,866 | 2021-08-13 | ||
| US202263297098P | 2022-01-06 | 2022-01-06 | |
| US63/297,098 | 2022-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202302095A true TW202302095A (zh) | 2023-01-16 |
Family
ID=80786345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111107087A TW202302095A (zh) | 2021-02-25 | 2022-02-25 | 使用bet抑制劑治療骨髓纖維化 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12357621B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4297750A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024507938A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230148208A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022227673B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206708A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023002497A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304697A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023009858A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202302095A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022182857A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202307538B (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EP4351560A4 (en) | 2021-06-08 | 2025-06-04 | The Regents of the University of California | ANTI-CANCER COMPOUNDS |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EA201990240A1 (ru) * | 2013-12-24 | 2019-06-28 | Бристол-Маерс Сквибб Компани | Новые трициклические соединения в качестве противораковых средств |
| MA43037A (fr) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Inst Inc | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
| WO2020051572A1 (en) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| MY209349A (en) | 2018-09-25 | 2025-07-03 | Impact Biomedicines Inc | Methods of treating myeloproliferative disorders |
| DK3908281T3 (da) * | 2019-01-09 | 2024-10-21 | Celgene Corp | Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom |
| US12559463B2 (en) | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
| HRP20251457T1 (hr) * | 2020-06-03 | 2026-01-02 | Incyte Corporation | Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi |
-
2022
- 2022-02-24 EP EP22708261.7A patent/EP4297750A1/en active Pending
- 2022-02-24 CA CA3206708A patent/CA3206708A1/en active Pending
- 2022-02-24 WO PCT/US2022/017678 patent/WO2022182857A1/en not_active Ceased
- 2022-02-24 KR KR1020237031973A patent/KR20230148208A/ko active Pending
- 2022-02-24 AU AU2022227673A patent/AU2022227673B2/en active Active
- 2022-02-24 MX MX2023009858A patent/MX2023009858A/es unknown
- 2022-02-24 JP JP2023551767A patent/JP2024507938A/ja active Pending
- 2022-02-25 US US17/680,569 patent/US12357621B2/en active Active
- 2022-02-25 TW TW111107087A patent/TW202302095A/zh unknown
-
2023
- 2023-07-24 IL IL304697A patent/IL304697A/en unknown
- 2023-07-28 ZA ZA2023/07538A patent/ZA202307538B/en unknown
- 2023-08-23 CL CL2023002497A patent/CL2023002497A1/es unknown
-
2025
- 2025-06-12 US US19/236,392 patent/US20250367174A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL304697A (en) | 2023-09-01 |
| US12357621B2 (en) | 2025-07-15 |
| CA3206708A1 (en) | 2022-09-01 |
| AU2022227673A9 (en) | 2024-09-19 |
| JP2024507938A (ja) | 2024-02-21 |
| WO2022182857A1 (en) | 2022-09-01 |
| KR20230148208A (ko) | 2023-10-24 |
| AU2022227673B2 (en) | 2026-06-04 |
| MX2023009858A (es) | 2023-09-12 |
| ZA202307538B (en) | 2026-01-28 |
| EP4297750A1 (en) | 2024-01-03 |
| CL2023002497A1 (es) | 2024-01-12 |
| AU2022227673A1 (en) | 2023-08-17 |
| US20250367174A1 (en) | 2025-12-04 |
| US20220265617A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250367174A1 (en) | Bet inhibitors as a treatment for myelofibrosis | |
| JP2023515817A (ja) | ダブラフェニブ、erk阻害剤及びshp2阻害剤を含む三重の医薬品の組合せ | |
| JP2024012493A (ja) | 消化管間質腫瘍の治療のための併用療法 | |
| JP6090836B2 (ja) | 化学療法剤の抗腫瘍活性増強剤 | |
| US20090312290A1 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
| RU2494736C2 (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| CN113274392A (zh) | 用于治疗慢性咳嗽的奥维匹坦 | |
| KR20230031242A (ko) | 골수증식성 신생물의 치료를 위한 병용 요법 | |
| US10576050B2 (en) | Methods and compositions for treatment of cancer | |
| KR20220124739A (ko) | 암의 치료를 위한 병용 요법 | |
| TW200808313A (en) | Compositions and methods for treating rheumatoid arthritis | |
| US9018176B2 (en) | Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders | |
| JP2011507880A (ja) | 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤 | |
| EA050366B1 (ru) | Применение ингибиторов bet отдельно или в комбинации с федратинибом или с руксолитинибом для лечения гематологического злокачественного новообразования, такого как миелофиброз | |
| CN117615759A (zh) | Bet抑制剂单独或者与菲卓替尼或芦可替尼组合用于治疗血液恶性肿瘤如骨髓纤维化的用途 | |
| WO2023011488A1 (zh) | 一种药物组合及其用途 | |
| CN117177752A (zh) | 用于治疗mpnst的化合物和组合物 | |
| EP2298309B1 (en) | Antitumor agent, kit and method of treating cancer | |
| US20200188363A1 (en) | Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer | |
| US20080312250A1 (en) | Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide | |
| US20090176759A1 (en) | Leukemic stem cell ablation | |
| WO2025078276A1 (en) | Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma | |
| WO2025056055A1 (zh) | 新一代egfr抑制剂单药或联合使用在制备肿瘤疾病的药物中的应用 | |
| WO2025214358A1 (zh) | 用于治疗胰腺癌的药物及其用途 | |
| WO2007010014A2 (en) | Compositions for treatment of systemic mastocytosis |